3 citations
,
January 2016 in “Journal of Clinical & Cellular Immunology” Targeting CXCL10 may help treat alopecia areata.
1 citations
,
September 2025 in “Frontiers in Immunology” Alopecia areata involves complex immune dysregulation, mainly driven by Th1 activity, suggesting broader treatment strategies.
September 2025 in “Figshare” Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.
September 2025 in “Figshare” Alopecia areata involves complex immune responses, suggesting broader treatments could help.
September 2025 in “Figshare” Alopecia areata involves complex immune responses, suggesting broader treatments could help.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
June 2023 in “Research Square (Research Square)” Different immune responses cause hair loss in scalp diseases, with unique patterns in scalp psoriasis possibly protecting against hair loss.
106 citations
,
January 2013 in “Clinical and Developmental Immunology” Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.
1 citations
,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
4 citations
,
September 2019 in “Biomedical Papers/Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc Czech Republic” CD2 might be a new treatment target for patchy alopecia areata.
20 citations
,
September 2003 in “Journal of Investigative Dermatology” Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.
December 2012 in “Journal of Dermatological Science” Wnt/beta-catenin signaling in the skin helps fat cell development during hair growth and repair.
August 2025 in “Dermatology and Therapy” Alopecia areata involves specific gene changes and immune pathways, offering new treatment targets.
1 citations
,
October 2023 in “Egyptian Journal of Immunology” PCOS is linked to low-grade chronic inflammation.
1 citations
,
January 2025 in “Frontiers in Immunology” Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.
64 citations
,
July 2016 in “Journal of Immunology” Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.
July 2025 in “Malaria Journal” Resolving malaria-related lung issues doesn't rely on Alox12 and leaves some inflammation.
April 2018 in “Journal of Investigative Dermatology” Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.
April 2019 in “Journal of Investigative Dermatology” Eating grape powder may reduce the severity of skin allergy symptoms.
16 citations
,
December 2015 in “Journal of Investigative Dermatology” Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.
1 citations
,
October 2019 Neutrophils are important for causing chronic itch in atopic dermatitis, and blocking the CXCR3 receptor may reduce this itch.
Neutrophils are key in causing chronic itch in atopic dermatitis, and blocking CXCR3 could reduce this itch.
55 citations
,
April 2010 in “Cancer and Metastasis Reviews” TGFβ's manipulation of inflammation and immune cells affects cancer spread, suggesting new treatment strategies and biomarkers.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
14 citations
,
February 2023 in “Frontiers in immunology” Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
25 citations
,
December 2018 in “Human Molecular Genetics” The document concludes that certain mutations may contribute to the inflammation in hidradenitis suppurativa and suggests that targeting TNFα could be a treatment strategy.